The African Union (AU) has dropped plans to secure coronavirus vaccines from the Serum Institute of India because of supply concerns and is instead exploring options with the US drugmaker, Johnson & Johnson. The head of Africa’s Centres for Disease Control, John Nkengasong, said reliable supplies of vaccines were vital – and that Indian restrictions on exports had complicated things for Africa. He added that the AU’s decision had nothing to do with the possible link to blood clots in rare cases involving the Oxford-AstraZeneca vaccine which will still be supplied to Africa through the UN’s Covax scheme. India’s Serum Institute is licensed to make global supplies of AstraZeneca but Delhi has commandeered stocks to deal with surging infections. Mr Nkengasong said the AU had already signed a deal for up to 400 million single dose jabs from Johnson & Johnson.
SOURCE: BBC
More Stories
The Challenges Facing the New Leader of Africa’s Largest Economy are Simply Enormous
Understanding the Opinions of Africa’s Rising Generation
SA Reserve Bank Concerned about the Rand’s Recent Meltdown and Persistent Price Pressures
Africa’s Banking Sector Celebrates
ICYMI Sam Altman Made a Stop in Lagos
Is African Debt as Perilous as Foreign Lenders Assume?
Accra’s IPPs Threaten Shutdown Over Non-Payment
DRC To Change the Way it Does Business with China
Maputo Picks a Partner for its Hydro Plans
Results of the Kenya Small Firm Diaries study in Nairobi
Africa Day this Year Marks 60 Years since the Founding of the Organisation of African Unity
Zimbabwe Retailers Head to the Streets